Peptide Therapeutics: Contract API Manufacturing Market- Current and Future Market Opportunity Acros

Outsourcing provides a platform for establishing strategic collaborations, which eventually helps players to augment their expertise in this domain, through access to lucrative and innovative cost cutting peptide synthesis technologies offered by CMOs. We believe that, as more peptide drug candidates progress into late stage clinical trials, stakeholders are likely to depend more on CMOs for scaling up of their development and manufacturing processes. Moreover, given the success of certain blockbuster peptide drugs that are near patent expiry, such as (in alphabetical order) Lupron Depot, OZEMPIC and Victoza, a number of biosimilars are anticipated to enter the market in the near future. This is further likely to translate into a higher demand for contract development and manufacturing services.

The global overall peptide contract manufacturing market is estimated to be worth USD 3.9 billion by 2025, and this value is projected to reach USD 6.5 billion by 2030, growing at a CAGR of 15.8%, during the period 2020-2030. The outsourced component of the peptide API manufacturing market is likely to be worth USD 3.2 billion by 2030, growing at a CAGR of 11.2%, during the aforementioned time period. Whereas, the outsourced component of the peptide FDF manufacturing market is likely to be worth USD 2.5 billion by 2030, growing at a CAGR of 10.5%, during the aforementioned time period.

Presently, chemical method is preferred by CMOs for the manufacturing of peptide APIs and this trend is unlikely to change in the foreseen future. The contract manufacturing market for peptide APIs synthesized using liquid phase synthesis methods growing at a CAGR of 10.3%, whereas solid phase synthesis is likely to grow at a CAGR of 12.8%. On the other hand, the market for CMOs manufacturing peptide APIs using non-chemical / recombinant methods is expected to witness significant growth in the coming years as well.

The peptide API contract manufacturing market for large and very large companies / end-users is likely to be worth USD 2.2 billion by 2030, growing at a CAGR of 10.4%, during the period 2020-2030. On the other hand, as per the base case scenario of our forecast model, the share of mid-sized companies / end-users are likely to be worth USD 0.42 billion by 2030, growing at an annualized rate of 9.1%, during the period 2020-2030.

The peptide API contract manufacturing markets in Europe and North America are likely to grow at a CAGR of 12.1% and 10.3%, respectively. The higher growth rate of the European market can be attributed to the larger share of expansion initiatives that are being carried out in this region. For instance, in October 2019, Pepscan announced its plans to double its production capacity for therapeutic peptides and personalized peptide medicines at its Netherlands facility and in October 2017, CordenPharma announced an investment of USD 4.2 million for the expansion of its facility and upgradation of analytical equipment at its Germany facility. On the other hand, emerging markets within Asia Pacific and RoW are estimated to grow at an annualized rate of 11.4%. It is worth noting that North America has emerged as the current contract manufacturing hub for peptide therapeutics; further, the contract service revenues generated within the aforementioned region are estimated to be worth USD 1.1 billion by 2030. In addition, the peptide API contract manufacturing markets in Europe, and Asia Pacific and RoW are likely to be worth USD 1.0 billion and USD 1.1 billion by 2030, respectively.

Roots Analysis provides market research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis.